Renal Cell Carcinoma pp 83-102

Part of the Current Clinical Urology book series (CCU)

Prognostic Factors for Localized Renal Cell Carcinoma

Chapter

Abstract

Although surgical treatment is often curative for localized renal cell carcinoma (RCC), about 20–30% of those with localized disease at presentation will recur after initial treatment. Many clinical, histologic, and molecular factors have been identified that place patients with localized RCC at greater risk for recurrence or death. In this chapter, factors affecting RCC prognosis in patients with localized disease, including patient and tumor characteristics, as well as integrated prognostic algorithms developed for use prior to or after nephrectomy are reviewed. These prognostic tools allow for more accurate counseling of patients regarding their likely clinical course, help to classify patients with greatest potential to benefit from adjuvant treatments, and facilitate ongoing cancer surveillance.

References

  1. 1.
    Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell SC, Novick AC, Bukowski RM. Renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology, 9th ed., vol 4. Philadelphia: Saunders; 2007. p. 2672–731.Google Scholar
  4. 4.
    Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am. 1993;20(2):247–62.PubMedGoogle Scholar
  5. 5.
    Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14(5):288–301.PubMedCrossRefGoogle Scholar
  7. 7.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRefGoogle Scholar
  8. 8.
    Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27(19):3225–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.PubMedGoogle Scholar
  11. 11.
    Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004;172(3):858–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004;172(6, Part 1 of 2):2167–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Ficarra V, Schips L, Guille F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. Cancer. 2005;104(7):1362–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173(1):48–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395–400.PubMedCrossRefGoogle Scholar
  18. 18.
    Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115:2092–103.PubMedCrossRefGoogle Scholar
  19. 19.
    Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Isbarn H, Karakiewicz PI. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol. 2009;19(3):247–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173(5):1496–501.PubMedCrossRefGoogle Scholar
  22. 22.
    Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma – can the 2002 primary tumor classification be improved? J Urol. 2005;173(3):716–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003;30(3):467–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Guinan P, Saffrin R, Stuhldreher D, Frank W, Rubenstein M. Renal cell carcinoma: comparison of the TNM and Robson stage groupings. J Surg Oncol. 1995;59(3):186–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology. 1995;45(1):34–40. discussion 40–1.PubMedCrossRefGoogle Scholar
  27. 27.
    Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996;155(6):1868–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Thompson RH, Leibovich BC, Cheville JC, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005;174(4 Pt 1):1218–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol. 2007;178(5):1878–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Bedke J, Buse S, Pritsch M, et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int. 2009;103(10):1349–54.PubMedCrossRefGoogle Scholar
  31. 31.
    Bertini R, Roscigno M, Freschi M, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol. 2009;181(5):2027–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Wotkowicz C, Wszolek MF, Libertino JA. Resection of renal tumors invading the vena cava. Urol Clin North Am. 2008;35(4):657–71. viii.PubMedCrossRefGoogle Scholar
  33. 33.
    Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol. 1994;151(5):1181–4.PubMedGoogle Scholar
  34. 34.
    Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology. 1997;49(1):28–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Paul R, Mordhorst J, Leyh H, Hartung R. Incidence and outcome of patients with adrenal metastases of renal cell cancer. Urology. 2001;57(5):878–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol. 2005;173(1):33–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Thompson RH, Leibovich BC, Cheville JC, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005;173(3):918–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Phillips CK, Taneja SS. The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol Oncol. 2004;22(3):214–23. discussion 223–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.PubMedGoogle Scholar
  40. 40.
    Targonski PV, Frank W, Stuhldreher D, et al. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients. J Urol. 1994;152:1389–92.Google Scholar
  41. 41.
    Hafez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162:1930.Google Scholar
  42. 42.
    Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol. 2001;165:1103.Google Scholar
  43. 43.
    Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68.Google Scholar
  44. 44.
    Von Knobloch R, Varga Z, Schrader AJ, et al. All patients with adrenal metastasis from RCC will eventually die in tumor progression: there is no cure or benefit from simultaneous adrenalectomy. J Urol. 2004;171:115.Google Scholar
  45. 45.
    Kanao K, Mizuno R, Kikuchi E et al: Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification. J Urol. 2009;181:480.Google Scholar
  46. 46.
    Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1971–9.Google Scholar
  47. 47.
    AJCC cancer staging manual, 7th ed. New York: Springer; 2010.Google Scholar
  48. 48.
    Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):992–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005;173(6):1889–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7. discussion 1027.PubMedCrossRefGoogle Scholar
  52. 52.
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178(1):41–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Lane BR, Gill IS. 7-Year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010;183(2):473–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival. J Urol. 2001;166(2):453–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Uzzo RG, Cherullo EE, Myles J, Novick AC. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol. 2002;167(6):2392–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol. 2000;24(3):451–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Klatte T, Chung J, Leppert JT, et al. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int. 2007;99(4):821–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007;178(2):440–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol. 2007;177(5):1703–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol. 2000;163(6):1671–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. Semin Urol Oncol. 2001;19(2):88–97.PubMedGoogle Scholar
  65. 65.
    Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003;169(3):909–16.PubMedCrossRefGoogle Scholar
  66. 66.
    Parekh DJ, Cookson MS, Chapman W, et al. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005;173(6):1897–902.PubMedCrossRefGoogle Scholar
  67. 67.
    Klatte T, Pantuck AJ, Riggs SB, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007;178(4 Pt 1):1189–95. discussion 1195.PubMedCrossRefGoogle Scholar
  68. 68.
    Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009;74(1):154–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004;171(2 Pt 1):598–601.PubMedCrossRefGoogle Scholar
  70. 70.
    Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;169(4):1282–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;171(2 Pt 1):588–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Montie JE, el Ammar R, Pontes JE, et al. Renal cell carcinoma with inferior vena cava tumor thrombi. Surg Gynecol Obstet. 1991;173(2):107–15.PubMedGoogle Scholar
  73. 73.
    Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol. 1996;155(2):448–50.PubMedCrossRefGoogle Scholar
  74. 74.
    Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol. 1999;162(1):46–50.PubMedCrossRefGoogle Scholar
  75. 75.
    Sweeney P, Wood CG, Pisters LL, et al. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003;21(5):327–33.PubMedCrossRefGoogle Scholar
  76. 76.
    Bissada NK, Yakout HH, Babanouri A, et al. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003;61(1):89–92.PubMedCrossRefGoogle Scholar
  77. 77.
    Lang H, Lindner V, Letourneux H, Martin M, Saussine C, Jacqmin D. Prognostic value of microscopic venous invasion in renal cell carcinoma: long-term follow-up. Eur Urol. 2004;46(3):331–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Ishimura T, Sakai I, Hara I, Eto H, Miyake H. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery. Int J Urol. 2004;11(5):264–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Dall’Oglio MF, Antunes AA, Sarkis AS, et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int. 2007;100(3):552–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Libertino JA, Zinman L, Watkins Jr E. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol. 1987;137(1):21–4.PubMedGoogle Scholar
  81. 81.
    Martinez-Salamanca JI, Huang WC, Millan I, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011;59(1):120–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Hatcher PA, Anderson EE, Paulson DF, Carson CC, Robertson JE. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991;145(1):20–3. discussion 23–4.PubMedGoogle Scholar
  83. 83.
    Zini L, Destrieux-Garnier L, Leroy X, et al. Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. J Urol. 2008;179(2):450–4.PubMedCrossRefGoogle Scholar
  84. 84.
    von Knobloch R, Schrader AJ, Walthers EM, Hofmann R. Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis. Urology. 2009;73(2):333–6.CrossRefGoogle Scholar
  85. 85.
    Bassil B, Dosoretz DE, Prout Jr GR. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1985;134(3):450–4.PubMedGoogle Scholar
  86. 86.
    Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–63.PubMedCrossRefGoogle Scholar
  87. 87.
    Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–41.PubMedCrossRefGoogle Scholar
  88. 88.
    Boumerhi G, Mekhail TM, Abou-Jawde RM, Malhi S, Olencki T, Leschinsky A. Prognostic factors for survival in previously treated patients with metastatic renal cell cancer. J Clin Oncol 2003;22(16s):abstract 1647Google Scholar
  89. 89.
    Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110(3):543–50.PubMedCrossRefGoogle Scholar
  91. 91.
    Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007;178(5):1901–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Maldazys JD, de Kernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136(2):376–9.PubMedGoogle Scholar
  93. 93.
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408–17.PubMedCrossRefGoogle Scholar
  94. 94.
    Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63. discussion 1763.PubMedCrossRefGoogle Scholar
  95. 95.
    Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98(12):2566–75.PubMedCrossRefGoogle Scholar
  96. 96.
    Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol. 2002;13(9):1460–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Kattan MW. Evaluating a new marker’s predictive contribution. Clin Cancer Res. 2004;10(3):822–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Pettus JA, Jang TL, Thompson RH, Yossepowitch O, Kagiwada M, Russo P. Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors. Mayo Clin Proc. 2008;83(10):1101–6.PubMedCrossRefGoogle Scholar
  100. 100.
    Berger DA, Megwalu II, Vlahiotis A, et al. Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology. 2008;72(2):359–63.PubMedCrossRefGoogle Scholar
  101. 101.
    Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13):3119–26.PubMedCrossRefGoogle Scholar
  102. 102.
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMedCrossRefGoogle Scholar
  103. 103.
    Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):981–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors – renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):994–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Altundag O, Altundag K, Gunduz E. Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol. 2005;23(5):1044. author reply 1044–5.PubMedCrossRefGoogle Scholar
  106. 106.
    Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol. 1989;7(3):158–71.PubMedGoogle Scholar
  107. 107.
    Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol. 1996;14(4):216–22.PubMedGoogle Scholar
  108. 108.
    Ather MH, Mithani S, Bhutto S, Adil S. Lupus type anticoagulant in a patient with renal cell carcinoma: an autoimmune paraneoplastic syndrome. J Urol. 2002;167(5):2129.PubMedCrossRefGoogle Scholar
  109. 109.
    Elias AN. New-onset insulinopenic diabetes mellitus in a patient with an incidentally discovered renal cell carcinoma. Am J Med. 2005;118(9):1047–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Magera Jr JS, Leibovich BC, Lohse CM, et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008;71(2):278–82.PubMedCrossRefGoogle Scholar
  111. 111.
    Pepper K, Jaowattana U, Starsiak MD, et al. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. J Gen Intern Med. 2007;22(7):1042–6.PubMedCrossRefGoogle Scholar
  112. 112.
    Klatte T, Said JW, Belldegrun AS, Pantuck AJ. Differential diagnosis of hypercalcemia in renal malignancy. Urology 2007;70(1):179.e7–8.Google Scholar
  113. 113.
    Massfelder T, Lang H, Schordan E, et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel–Lindau tumor suppressor gene. Cancer Res. 2004;64(1):180–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Moein MR, Dehghani VO. Hypertension: a rare presentation of renal cell carcinoma. J Urol. 2000;164(6):2019.PubMedCrossRefGoogle Scholar
  115. 115.
    Ljungberg B, Grankvist K, Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 1995;76(8):1435–9.PubMedCrossRefGoogle Scholar
  116. 116.
    O’Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002;168(4 Pt 1):1378–80.PubMedGoogle Scholar
  117. 117.
    Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007;110(6):1241–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev. 2002;11(3):245–52.PubMedCrossRefGoogle Scholar
  119. 119.
    Vaglio A, Buzio L, Cravedi P, Pavone L, Garini G, Buzio C. Prognostic significance of albuminuria in patients with renal cell cancer. J Urol. 2003;170(4 Pt 1):1135–7.PubMedCrossRefGoogle Scholar
  120. 120.
    Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000;86(3):203–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007;99(1):77–80.PubMedCrossRefGoogle Scholar
  122. 122.
    Johnson TV, Abbasi A, Owen-Smith A, et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol. 2010;183(2):480–5.PubMedCrossRefGoogle Scholar
  123. 123.
    Johnson TV, Abbasi A, Owen-Smith A, et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010;76(3):766.e1–5.Google Scholar
  124. 124.
    Lang H, Lindner V, de Fromont M, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with >15-year follow-up. Cancer. 2005;103(3):625–9.PubMedCrossRefGoogle Scholar
  125. 125.
    Ficarra V, Novara G, Galfano A, et al. The ‘stage, size, grade and necrosis’ score is more accurate than the University of California Los Angeles integrated staging system for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 2009;103(2):165–70.PubMedCrossRefGoogle Scholar
  126. 126.
    Ficarra V, Martignoni G, Lohse C, et al. External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol. 2006;175(4):1235–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.PubMedCrossRefGoogle Scholar
  128. 128.
    Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med. 2005;25(2):433–64.PubMedCrossRefGoogle Scholar
  129. 129.
    Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76(12):2543–9.PubMedCrossRefGoogle Scholar
  130. 130.
    Medeiros LJ, Jones EC, Aizawa S, et al. Grading of renal cell carcinoma: Workgroup No. 2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):990–1.PubMedCrossRefGoogle Scholar
  131. 131.
    Klatte T, Remzi M, Zigeuner RE, et al. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol. 2010;184(1):53–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162–9.PubMedCrossRefGoogle Scholar
  133. 133.
    Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69(2):230–5.PubMedCrossRefGoogle Scholar
  134. 134.
    Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196.PubMedCrossRefGoogle Scholar
  135. 135.
    Klatte T, Han KR, Said JW, et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008;26(6):604–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Cindolo L, de la Taille A, Schips L, et al. Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database. Urology. 2005;65(4):681–6.PubMedCrossRefGoogle Scholar
  137. 137.
    Zhou M. Pathology of renal cell carcinomas. In: Campbell SC, Rini BI, editors. Renal cell carcinoma. 1st ed. Shelton: People’s Medical Publishing House; 2009. p. 1–14.Google Scholar
  138. 138.
    Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer. 1987;59(3):516–26.PubMedCrossRefGoogle Scholar
  139. 139.
    DeLong W, Grignon DJ, Eberwein P, Shum DT, Wyatt JK. Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch Pathol Lab Med. 1993;117(6):636–40.PubMedGoogle Scholar
  140. 140.
    Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17(2):523–8.PubMedGoogle Scholar
  141. 141.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. In: WHO classification of tumors, vol 7. Lyon: IARC Press; 2004.Google Scholar
  142. 142.
    Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol. 1995;103(5):624–35.PubMedGoogle Scholar
  143. 143.
    Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Delahunt B. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology. 1999;31(3):185–90.PubMedCrossRefGoogle Scholar
  145. 145.
    de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275–84.PubMedCrossRefGoogle Scholar
  146. 146.
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18(2):551–5.PubMedGoogle Scholar
  147. 147.
    Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28(4):435–41.PubMedCrossRefGoogle Scholar
  148. 148.
    Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167(1):65–70.PubMedCrossRefGoogle Scholar
  149. 149.
    Dall’Oglio MF, Lieberknecht M, Gouveia V, Sant’Anna AC, Leite KR, Srougi M. Sarcomatoid differentiation in renal cell carcinoma: prognostic implications. Int Braz J Urol. 2005;31(1):10–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959–61.PubMedCrossRefGoogle Scholar
  151. 151.
    Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101(7):1545–51.PubMedCrossRefGoogle Scholar
  152. 152.
    Fujiwara Y, Kiura K, Tabata M, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs. 2008;19(4):431–3.PubMedCrossRefGoogle Scholar
  153. 153.
    Bangalore N, Bhargava P, Hawkins MJ, Bhargava P. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol. 2001;12(2):271–4.PubMedCrossRefGoogle Scholar
  154. 154.
    Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104(3):511–20.PubMedCrossRefGoogle Scholar
  155. 155.
    Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103(12):2517–25.PubMedCrossRefGoogle Scholar
  156. 156.
    Steinbach F, Stockle M, Griesinger A, et al. Multifocal renal cell tumors: a retrospective analysis of 56 patients treated with radical nephrectomy. J Urol. 1994;152(5 Pt 1):1393–6.PubMedGoogle Scholar
  157. 157.
    Baltaci S, Orhan D, Soyupek S, Beduk Y, Tulunay O, Gogus O. Influence of tumor stage, size, grade, vascular involvement, histological cell type and histological pattern on multifocality of renal cell carcinoma. J Urol. 2000;164(1):36–9.PubMedCrossRefGoogle Scholar
  158. 158.
    Lang H, Lindner V, Martin M, et al. Prognostic value of multifocality on progression and survival in localized renal cell carcinoma. Eur Urol. 2004;45(6):749–53.PubMedCrossRefGoogle Scholar
  159. 159.
    Dimarco DS, Lohse CM, Zincke H, Cheville JC, Blute ML. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology. 2004;64(3):462–7.PubMedCrossRefGoogle Scholar
  160. 160.
    Richstone L, Scherr DS, Reuter VR, et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol. 2004;171(2 Pt 1):615–20.PubMedCrossRefGoogle Scholar
  161. 161.
    Blute ML, Thibault GP, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence. J Urol. 2003;170(3):760–3.PubMedCrossRefGoogle Scholar
  162. 162.
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612–24.PubMedCrossRefGoogle Scholar
  163. 163.
    Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59(4):532–7.PubMedCrossRefGoogle Scholar
  164. 164.
    Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604–14.PubMedCrossRefGoogle Scholar
  165. 165.
    Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281–91.PubMedCrossRefGoogle Scholar
  166. 166.
    Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology. 2003;62(4):641–6.PubMedCrossRefGoogle Scholar
  167. 167.
    Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11(1):71–7.PubMedCrossRefGoogle Scholar
  168. 168.
    Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763–71.PubMedCrossRefGoogle Scholar
  169. 169.
    Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.PubMedCrossRefGoogle Scholar
  170. 170.
    Dall’Oglio MF, Antunes AA, Pompeo AC, Mosconi A, Leite KR, Srougi M. Prognostic relevance of the histological subtype of renal cell carcinoma. Int Braz J Urol. 2008;34(1):3–8.PubMedCrossRefGoogle Scholar
  171. 171.
    Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008;112(7):1480–8.PubMedCrossRefGoogle Scholar
  172. 172.
    Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33. discussion 33–4.PubMedCrossRefGoogle Scholar
  173. 173.
    Carter MD, Tha S, McLoughlin MG, Owen DA. Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol. 1992;147(4):1096–8.PubMedGoogle Scholar
  174. 174.
    Chao D, Zisman A, Pantuck AJ, et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002;167(1):71–4.PubMedCrossRefGoogle Scholar
  175. 175.
    Mejean A, Roupret M, Larousserie F, Hopirtean V, Thiounn N, Dufour B. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J Urol. 2003;169(4):1287–90.PubMedCrossRefGoogle Scholar
  176. 176.
    Polascik TJ, Bostwick DG, Cairns P. Molecular genetics and histopathologic features of adult distal nephron tumors. Urology. 2002;60(6):941–6.PubMedCrossRefGoogle Scholar
  177. 177.
    Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006;176(1):40–3. discussion 43.PubMedCrossRefGoogle Scholar
  178. 178.
    Kobayashi N, Matsuzaki O, Shirai S, Aoki I, Yao M, Nagashima Y. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39(9):1350–9.PubMedCrossRefGoogle Scholar
  179. 179.
    Davis Jr CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11.PubMedCrossRefGoogle Scholar
  180. 180.
    Lane BR, Campbell SC, Remer EM, et al. Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristics. Urology. 2008;71(6):1142–8.PubMedCrossRefGoogle Scholar
  181. 181.
    Gong K, Zhang N, He Z, Zhou L, Lin G, Na Y. Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. J Cancer Res Clin Oncol. 2008;134(4):433–7.PubMedCrossRefGoogle Scholar
  182. 182.
    Ferlicot S, Allory Y, Comperat E, et al. Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature. Virchows Archiv. 2005;447(6):978–83.PubMedCrossRefGoogle Scholar
  183. 183.
    Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s–9.PubMedCrossRefGoogle Scholar
  184. 184.
    Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94(20):1569–75.PubMedCrossRefGoogle Scholar
  185. 185.
    Smits KM, Schouten LJ, van Dijk BA, et al. Genetic and epigenetic alterations in the von Hippel–Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res. 2008;14(3):782–7.PubMedCrossRefGoogle Scholar
  186. 186.
    Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539–42.PubMedCrossRefGoogle Scholar
  187. 187.
    Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006;3(1):e13.PubMedCrossRefGoogle Scholar
  188. 188.
    Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98(17):9754–9.PubMedCrossRefGoogle Scholar
  189. 189.
    Higgins JP. Gene array studies in renal neoplasia. Sci World J. 2006;6:502–11.CrossRefGoogle Scholar
  190. 190.
    Young AN, Master VA, Paner GP, Wang MD, Amin MB. Renal epithelial neoplasms: diagnostic applications of gene expression profiling. Adv Anat Pathol. 2008;15(1):28–38.PubMedCrossRefGoogle Scholar
  191. 191.
    Gieseg MA, Cody T, Man MZ, Madore SJ, Rubin MA, Kaldjian EP. Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics. 2002;3(1):26.PubMedCrossRefGoogle Scholar
  192. 192.
    Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001;11(11):1861–70.PubMedGoogle Scholar
  193. 193.
    Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154(4):981–6.PubMedCrossRefGoogle Scholar
  194. 194.
    Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005;205(3):377–87.PubMedCrossRefGoogle Scholar
  195. 195.
    Vasselli JR, Shih JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A. 2003;100(12):6958–63.PubMedCrossRefGoogle Scholar
  196. 196.
    Skubitz KM, Skubitz AP. Differential gene expression in renal-cell cancer. J Lab Clin Med. 2002;140(1):52–64.PubMedCrossRefGoogle Scholar
  197. 197.
    Huo L, Sugimura J, Tretiakova MS, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36(3):262–8.PubMedCrossRefGoogle Scholar
  198. 198.
    Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol. 2005;173(6):2150–3.PubMedCrossRefGoogle Scholar
  199. 199.
    Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1):69–76.PubMedCrossRefGoogle Scholar
  200. 200.
    Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65(13):5628–37.PubMedCrossRefGoogle Scholar
  201. 201.
    Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10(16):5464–71.PubMedCrossRefGoogle Scholar
  202. 202.
    Liu X, Minin V, Huang Y, Seligson DB, Horvath S. Statistical methods for analyzing tissue microarray data. J Biopharm Stat. 2004;14(3):671–85.PubMedCrossRefGoogle Scholar
  203. 203.
    Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.PubMedGoogle Scholar
  204. 204.
    Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25(30):4757–64.PubMedCrossRefGoogle Scholar
  205. 205.
    Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.PubMedCrossRefGoogle Scholar
  206. 206.
    Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171(6 Pt 1):2461–6.PubMedCrossRefGoogle Scholar
  207. 207.
    Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009;115(10 Suppl):2327–33.PubMedCrossRefGoogle Scholar
  208. 208.
    Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res. 2010;30(3):987–92.PubMedGoogle Scholar
  209. 209.
    Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106(6):772–8.PubMedCrossRefGoogle Scholar
  210. 210.
    Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6):379–85.PubMedCrossRefGoogle Scholar
  211. 211.
    Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174–9.PubMedCrossRefGoogle Scholar
  212. 212.
    Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5.PubMedCrossRefGoogle Scholar
  213. 213.
    Krambeck AE, Dong H, Thompson RH, et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1749–56.PubMedCrossRefGoogle Scholar
  214. 214.
    Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007;13(2 Pt 2):709s–15.PubMedCrossRefGoogle Scholar
  215. 215.
    Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007;110(4):783–90.PubMedCrossRefGoogle Scholar
  216. 216.
    Sorbellini M, Kattan MW, Snyder ME, Hakimi AA, Sarasohn DM, Russo P. Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol. 2006;176(2):472–6. discussion 476.PubMedCrossRefGoogle Scholar
  217. 217.
    Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28(2):311–7.PubMedCrossRefGoogle Scholar
  218. 218.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8.PubMedCrossRefGoogle Scholar
  219. 219.
    Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179(6):2146–51. discussion 2151.PubMedCrossRefGoogle Scholar
  220. 220.
    Yaycioglu O, Rutman MP, Balasubramaniam M, Peters KM, Gonzalez JA. Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors. Urology. 2002;60(1):33–8.PubMedCrossRefGoogle Scholar
  221. 221.
    Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92(9):901–5.PubMedCrossRefGoogle Scholar
  222. 222.
    Jeldres C, Sun M, Liberman D, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9.PubMedCrossRefGoogle Scholar
  223. 223.
    Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol. 2009;55(2):287–95.PubMedCrossRefGoogle Scholar
  224. 224.
    Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy – a renaissance? J Urol. 2008;179(1):20–7.PubMedCrossRefGoogle Scholar
  225. 225.
    Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.PubMedCrossRefGoogle Scholar
  226. 226.
    Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.PubMedCrossRefGoogle Scholar
  227. 227.
    Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010;57:102–9.PubMedCrossRefGoogle Scholar
  228. 228.
    Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol. 2007;177(2):477–80.PubMedCrossRefGoogle Scholar
  229. 229.
    Lane BR, Poggio ED, Herts BR, Novick AC, Campbell SC. Renal function assessment in the era of chronic kidney disease: renewed emphasis on renal function centered patient care. J Urol. 2009;182(2):435–43. discussion 443–4.PubMedCrossRefGoogle Scholar
  230. 230.
    Lane BR, Fergany AF, Weight CJ, Campbell SC. Renal functional outcomes after partial nephrectomy with extended ischemic intervals are better than after radical nephrectomy. J Urol. 2010;184(4):1286–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Urology DivisionSpectrum Health Medical GroupGrand RapidsUSA
  2. 2.Michigan State University College of Human MedicineGrand RapidsUSA
  3. 3.Van Andel InstituteGrand RapidsUSA

Personalised recommendations